Hemogenyx Pharmaceuticals (LON:HEMO) Posts Quarterly Earnings Results

Hemogenyx Pharmaceuticals (LON:HEMO) released its quarterly earnings data on Monday. The company reported GBX (101.70) earnings per share (EPS) for the quarter, Digital Look Earnings reports.

Hemogenyx Pharmaceuticals Stock Up 1.7%

Hemogenyx Pharmaceuticals stock opened at GBX 472 on Monday. Hemogenyx Pharmaceuticals has a 12 month low of GBX 356 and a 12 month high of GBX 1,345. The stock has a fifty day simple moving average of GBX 581.56 and a two-hundred day simple moving average of GBX 738.50. The company has a current ratio of 1.38, a quick ratio of 6.72 and a debt-to-equity ratio of 167.66. The firm has a market cap of £32.10 million, a price-to-earnings ratio of -2.77 and a beta of 1.49.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.